跳至主要内容
临床试验/NCT00002344
NCT00002344已完成1 期

Double-Blind Crossover Study Assessing the Dose Proportionality of Azithromycin Tablets in HIV-Infected Subjects

Pfizer1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
12
试验地点
1

研究概览

简要总结

To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients.

The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.

详细描述

The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.

Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment, two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out periods.

研究设计

研究类型
Interventional
干预模型
Parallel
主要目的
Treatment

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients must have:
  • •HIV seropositivity.
  • •CD4 count <= 500 cells/mm
  • •NO active AIDS opportunistic infection.

排除标准

  • •Co-existing Condition:
  • •Patients with the following symptoms or conditions are excluded:
  • •Other active intercurrent illness.
  • •Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies.
  • •Signs or symptoms of severe illness that would preclude study participation.
  • •Known allergies to macrolide antibiotics.
  • •Patients with the following prior condition are excluded:
  • •Clinically important change in baseline status within 4 weeks prior to study entry.
  • •Prior Medication:
  • •Investigational drugs including treatment IND drugs within 4 weeks prior to study entry.
  • •Known drug or alcohol dependence.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验